MELANOMA STAGE IV

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that has stopped responding to standard immunotherapy. About 14 adults with stage III or IV melanoma that cannot …

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma. About 90 adults with stage III or IV melanoma will receive treatment based on their tumor's biomarkers. The goal is to see if this approach leads to better tumor shrinkage …

This study tests whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be surgically removed. About 25 adults with stage III or IV melanoma will receive the drug combination. The goal is to see how many pa…

This early-stage study tests a new daily pill, GIM-531, for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by targeting specific immune cells to help the body fight cancer. Researchers will check safety and find the best dose…

This study is for people with high-risk melanoma who have tiny bits of tumor DNA still in their blood after surgery. It compares a two-drug immunotherapy combo against a single drug to see which better clears these hidden cancer cells. About 54 participants will be randomly assig…

This study looks at whether giving additional treatment after surgery can reduce the chance of melanoma returning in people with advanced stage III or IV melanoma that has a BRAF V600 mutation. About 50 participants will receive a combination of drugs (encorafenib and binimetinib…

This study tests a combination of three immunotherapy drugs (IL2, ipilimumab, and nivolumab) in people with advanced melanoma that can't be removed by surgery and has stopped responding to prior anti-PD1 treatment. The goal is to see if this new approach can shrink tumors or slow…

This study compares two treatments for people with advanced melanoma that has spread to the brain. One group gets standard immunotherapy drugs (ipilimumab and nivolumab) alone, while the other group also receives targeted radiation to brain tumors. The goal is to see if adding ra…

This early-phase trial tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a specific marker called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recogn…

This study tests a new treatment called [212Pb]VMT01, which delivers targeted radiation to melanoma cells. It is for people with advanced melanoma that has not responded to prior treatments. The study will see if this therapy is safe and effective when used alone or with another …

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with another drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals a…

This study tests whether beta-glucan, a natural fiber from yeast, can improve the immune response in people with stage III or IV melanoma who are already taking the immunotherapy drug pembrolizumab. Researchers will measure changes in immune cells from blood samples. The goal is …

This study looks at whether combining a special PET/CT scan with a blood test for tumor DNA can help doctors predict which patients with advanced melanoma will respond to immunotherapy. About 24 adults with stage III or IV melanoma will have their scans and blood tested before an…

This study follows about 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, overall health, and any return of cancer. The goal is to understand the long-term safety of this treatment.